Current Price - $1.08
Price Target - $5 , Low Price Target- $4.78 , High Price Target - $6.51( StockInvest.us)
Quote -"The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 445.99% during the next 3 months and, with a 90% probability hold a price between $4.78 and $6.51 at the end of this 3-month period." - StockInvest ( https://stockinvest.us/stock/GHSI#:~:text=Given%20the%20current%20short-term,of%20this%203-month%20period )
Guardion is a specialty health sciences company that develops clinically supported nutrition, medical foods, nutraceuticals and medical devices, with a focus in the ocular health marketplace. Located in San Diego, California, the Company combines targeted nutrition with innovative, evidence-based diagnostic technology. Guardion boasts impressive Scientific and Medical Advisory Boards.
->Guardion Health Sciences has received Regulatory Product Registration Approval for Second Immune Support Dietary Supplement Designed and Produced by Guardion Health Sciences
The product registration, which is valid for five years and is renewable, is an important step toward commercialization by HWGB. Astramern Astra H comes in capsule form and contains specifically formulated herbs that are believed to help boost the body’s immune system.
This product registration approval is the second such approval received by HWGB using a Guardion-developed product. In August 2020, the Company announced the product registration approval of the vitamin formulation Astramern Nutra V. Previously, in early 2020, HWGB had entered into a Manufacturing and Supply Agreement for Guardion to design and manufacture both immune support dietary supplements, which are to be packaged together for sale by HWGB in Malaysia. HWGB’s healthcare subsidiary, Astramern Sdn Bhd, has an exclusive license to use and distribute these products in certain territories. Guardion fulfilled HWGB’s initial product order of $890,000 in June 2020.
->Guardion Health Sciences Announces Development of New Vision/Energy Support Drink – EPIQ-V
Epiq-V contains Lutein, a primary ingredient in the Company’s flagship product, Lumega-Z, and is being developed for an adult market as a vision health and support product concurrently with a second formulation for introduction as a visual attention and energy drink primarily focused on the youth market to support video gaming and other close-up device viewing requirements for this age group. The initial round of testing has been completed and the final round is currently underway and expected to be completed by the end of the first quarter of 2021. The commercial product is expected to be available 12 to 16 weeks after the final round of testing. With respect to the Asian market, specifically China, the Company has already filed and been granted a trademark (utilizing Chinese characters) for the Epiq-V brand name. Trademark protection for the brand has also been submitted for approval in the United States.
These products are aimed at the ocular health market. In its pipeline of products are various medical foods such as Lumega-Z, GlaucoCetin, and more. GHSI produces an extensive range of testing and diagnostic tools used in ocular settings on the medical devices side. A few weeks ago, the company stated that it received product approval from the Malaysian National Pharmaceutical Regulatory Agency or NPRA.
The company also announced that Ho Wah Genting Berhad would be the exclusive distributor of the product in Malaysia. Bret Scholtes, CEO of Guardion, stated that “a key part of our strategy includes expansion into foreign markets, either through licensing, supply and distribution agreements, or direct marketing opportunities. Additionally, this relationship with HWGB is important, as it allows the Company to develop new products that widen our scope in terms of health applications.”
Short Summary with Extras
-Guardion Health Sciences is a company based out of San Diego, Calif., with a focus on developing nutrition, medical food, and medical devices.
-Chief among its targets is the ocular health market. The first medical food released by the company was Lumega-Z. -This is a food that has been used clinically since 2012 to help restore lost vision. It has been shown to be effective at restoring vision in those suffering from early loss due to macular degeneration.
-One thing that investors will want to note is that medical food is not the same as a drug. Instead, it’s a supplement designed for the dietary needs of patients suffering from specific diseases.
->Guardion Health Sciences also makes the MapcatSF. This is a device that measures the macular pigment on a patient’s eyes. The loss of this pigment is what can lead to early vision loss.It’s also what the company seeks to restore with Lumega-Z.